This prediction model identifies a number of potentially reversible factors responsible for prolonging LOS and may enable the development of more accurate risk-adjusted methods with which to improve or compare care. (Am Heart J 2001;142:799-805.) 
declined substantially after coronary stenting, 15 LOS still remains an important determinant of the associated health care costs. 16 Although clinical and procedural predictors of prolonged hospital stay after PTCA have been identified (eg, advanced age, unstable angina, multivessel coronary artery disease, complex coronary lesions, and angiographic luminal filling defects), 17 little is known about factors that drive LOS in patients undergoing coronary stenting without anticoagulation 18 and by a femoral arterial access site. 19 The development of LOS prediction models would be useful. They could identify potentially reversible causative factors at different stages in the care process and enable providers, insurers, and payors to develop more accurate risk-adjusted methods with which to improve or compare care. We conducted this study to identify LOS predictors among patients undergoing coronary stenting.
Methods

Study subjects
Study subjects were identified from an ongoing interventional cardiology registry containing clinical, procedural, therapeutic, and outcome data prospectively collected for the purpose of monitoring and improving the quality of care. A cohort of consecutive registry patients undergoing coronary stent placement and treated with the antiplatelet agents aspirin and ticlopidine was identified at our center between February 14,  Coronary stenting is the preferred treatment for acute or threatened closure after percutaneous transluminal coronary angioplasty (PTCA) [1] [2] [3] and is associated with lower rates of restenosis than is stand-alone PTCA. [4] [5] [6] Until recently, coronary stenting had been limited by stent thrombosis, as well as by bleeding and vascular complications resulting from the aggressive anticoagulation regimens used in an effort to prevent this phenomenon. 7 Advances in procedural technique, 8 periprocedural care, 9 and adjunctive pharmacologic management [10] [11] [12] [13] have greatly reduced the risk of these complications while maintaining or improving the benefits of coronary stenting. Concurrent with the dramatic decrease in complication rates, the number of coronary stent procedures performed has grown exponentially. In 1997, it was estimated that 686,000 coronary stent procedures were performed in the United States. 14 
Although the postprocedure length of stay (LOS) has
Background Postprocedure length of stay (LOS) remains an important determinant of medical costs after coronary stenting. Variables that predict LOS in this setting have not been well characterized.
Methods
We evaluated 359 consecutive patients who underwent coronary stenting with antiplatelet therapy. Sequential multiple linear regression (MLR) models were constructed with use of 4 types of variables to predict log-transformed LOS: preprocedure, intraprocedure, and postprocedure factors and adverse outcomes.
Results Preprocedure factors alone explained more than one third of the variability in postprocedure LOS (adjusted R 2 = 0.37). The addition of procedural variables added little to the model (adjusted R 2 = 0.39). Entering nonoutcome postprocedure variables significantly enhanced the predictive capacity of the model, explaining more than half the variability in postprocedure LOS (adjusted R 2 = 0.54). In the final model, addition of outcome variables increased its predictive capacity only slightly (adjusted R 2 = 0.61). In this model, significant preprocedure factors included: myocardial infarction (MI) within 24 hours, MI within 1 to 30 days, women with peripheral vascular disease, intravenous heparin, and chronic atrial fibrillation. High-risk intervention was the only significant intraprocedure variable. Significant postprocedure factors included periprocedure ischemia; cerebrovascular accident or transient ischemic attack; treatment with intravenous heparin or nitroglycerin or intra-aortic balloon pump; and need for blood transfusion. Significant adverse outcomes included contrast nephropathy, gastrointestinal bleeding, arrhythmia, vascular complication, and repeat angiography.
1995, and March 31, 1997. Stenting was performed through the femoral artery in standard fashion. Same-day sheath removal timed to a fall in activated clotting time to <150 seconds was routine. Those patients undergoing subsequent cardiac surgical procedures (eg, coronary artery bypass graft [CABG] , left ventricular assist device [LVAD]), and those who died during the index hospitalization were excluded.
Selected variable definitions
Hypercholesterolemia was defined as an abnormally elevated cholesterol level by standard National Cholesterol Education Program criteria 20 or treatment with a lipid-lowering agent. A current smoker was defined as consuming at least a half pack of cigarettes per day at the time of admission or during the 3 months before admission. Obesity was defined by use of sex-specific National Health and Nutrition Examination Survey III criteria (body mass index of 27.3 kg/m 2 for women and 27.8 kg/m 2 for men). 21 Recent history of congestive heart failure (CHF) reflected a decompensation within the 6 weeks before admission. Renal insufficiency indicated an admission serum creatinine above the institutional upper limit of normal. Unstable angina was defined as angina at rest, new-onset exertional angina of at least Canadian Cardiovascular Class III in severity, 22 or recent accelerated angina. Q-wave myocardial infarction (MI) was defined as the development of electrocardiographic Q waves, 0.04 seconds in width or more than one third of the total QRS complex height in 2 contiguous leads and as evidenced by a subsequent 3-fold rise in creatine kinase-myocardial band fraction (CK-MB) over the institutional norm. Non-Q-wave MI was defined as any rise in CK-MB above the institutional norm without the concurrent electrocardiographic Q waves. A high-risk intervention denoted coronary stent procedures with a high risk of associated morbidity or mortality because the target vessel supplied collateral circulation to occluded coronary vessels or because stenting took place in the presence of an unprotected left main (LM) coronary artery. Multiple stents indicated that 2 or more stents were placed in the target lesion. Modified American College of Cardiology/American Heart Association lesion types have been well defined elsewhere. 23 For the purposes of this study, a complex coronary lesion refers to one that is type B2 or C. Nadir hematocrit (Hct) was recorded after the procedure.
Outcomes
LOS was defined as the number of days from procedure until discharge and was recorded to the nearest 1-day increment. Periprocedure angina indicated angina, during or after coronary stenting, lasting >30 minutes despite medical therapy. Periprocedure MI included both Q-and non-Q-wave events. Periprocedure ischemia included patients with either periprocedure angina or MI. Arrhythmia was defined as ventricular tachycardia or fibrillation requiring pharmacologic or mechanical therapy. Vascular complications included pseudoaneurysm, arteriovenous fistula, femoral neuropathy, retroperitoneal hematoma, vascular access site hematoma, or any other vascular access site complication requiring transfusion or causing a drop in hemoglobin of >3 g/dL. Contrast nephropathy was defined as acute renal insufficiency evidenced by an increase in serum creatinine to >2.0 mg/dL or a 50% increase above a preprocedure abnormal baseline. Transfusion included administration of any blood products.
Data collection
Clinical and procedural data were collected by an interventional cardiologist during the index hospitalization. In-hospital therapeutic data, adverse patient outcomes, and LOS were recorded prospectively by a nurse practitioner who followed up patients from the time of coronary stenting until hospital discharge. All adverse outcomes were later physician-verified by medical record review.
Statistical analysis
Categorical variables are expressed as frequencies and percents. Continuous variables appear as means ± SD when normally distributed and as medians with interquartile ranges when non-Gaussian. The χ 2 test and the Fisher exact test were used for bivariate analyses of categorical variables. The MannWhitney rank sum test was used to compare median LOS for all categorical variables. Simple linear regression was used, after natural log-transforming LOS (log e [LOS] ), for all continuous variables. This transformation was undertaken given the inherently skewed distribution of LOS.
Variables were eligible for consideration as candidate predictors when bivariate analyses suggested an association between that variable and LOS (P ≤ .2). Candidate clinical, procedural, therapeutic and adverse outcome predictor variables were consecutively entered into multivariable linear regression (MLR) models to predict log e (LOS). In all, 4 MLR models were constructed. The first contained variables identifiable before coronary stenting. The second added variables that became available during the procedure. The third model introduced postprocedure variables, excluding adverse outcomes. The fourth model included outcome variables as well. Multiple preliminary selection techniques were applied to candidate predictor variables and interaction terms (the latter were created when associations existed between 2 predictor variables and when the interaction was plausible), including adjusted R 2 , the Mallow C p , and forward stepwise selection. 24 Final multivariable models were chosen when they were identified by multiple model selection techniques and parsimonious, as gauged by the PRESS p (prediction sum of squares) criterion. 24 A model α level of .05 was considered statistically significant. The adjusted R 2 criterion was used to gauge the degree to which these models predicted log e (LOS). All statistics were performed with SAS statistical software version 6.12 (SAS Institute, Cary, NC).
Results
Study subjects
Three hundred seventy-three patients underwent coronary stenting with antiplatelet therapy at our institution during the study time period. Of these, 3 underwent CABG, 1 received an LVAD, and 9 died during the index hospitalization. In addition, 1 patient underwent stenting for Takayasu's arteritis. The remaining 359 patients (96%) were included in this analysis. Overall, they were at high risk, characterized by a median age (range) of 62 (22-89) years, a preponderance of men, and a high prevalence of comorbidities; the majority of these patients were treated in the setting of an acute coronary syndrome. The distribution of LOS was highly skewed, with a median of 1 and a range of 1 to 38 days (Figure 1 ). Overall, 55% of patients were discharged from the hospital within 1 day of their coronary intervention, 81% within 3 days, 91% within 5 days, and 98% within 10 days. Patient characteristics and adverse clinical outcomes are displayed with corresponding LOS in Tables IA and IB. Bivariate analyses of LOS Median LOS after coronary stenting was longer in older patients; women; those with diabetes, peripheral vascular disease, a history of cerebrovascular accident or transient ischemic attack, recent history of congestive heart failure decompensation, congestive heart failure on admission, or any history of MI; in the setting of cardiogenic shock; in patients treated with intravenous heparin or nitroglycerin (NTG) or an intra-aortic balloon pump (IABP) before the procedure. Furthermore, LOS was increased in the setting of multivessel disease, in those undergoing high-risk interventions, when stenting was complicated by acute closure or no reflow, and when intravenous heparin or NTG, IABP, or a blood product transfusion was administered after the procedure. Finally, log e (LOS) rose with falling baseline Hct among those patients with available baseline Hct values (n = 321).
A number of adverse clinical outcomes were also associated with longer median LOS, including periprocedure angina, periprocedure MI, or a composite of either of these outcomes (ie, periprocedure ischemia). LOS was also prolonged in the setting of postprocedure arrhythmias, gastrointestinal (GI) bleeding, vascular complications, contrast nephropathy, repeat angiography, and repeat PTCA.
Multivariable analyses of LOS
When candidate preprocedure variables were entered into an MLR model to predict log e (LOS), the most predictive yet parsimonious model included the following significant predictors in descending order of importance: MI 0 to 24 hours before stenting, MI 1 to 30 days before stenting, women with peripheral vascular disease, diabetes, preprocedure intravenous heparin, and chronic atrial fibrillation. Other variables that appeared in the final model but did not reach the conventional level of statistical significance included history of cerebrovascular accident or transient ischemic attack, cardiogenic shock, and female sex (model-adjusted R 2 = 0.37, P = .0001) (Table II) . Preprocedure IABP and preprocedure NTG were excluded from the modeling process because these variables were less predictive than but highly collinear with cardiogenic shock and preprocedure intravenous heparin, respectively. In addition, baseline Hct was not considered in multivariable models because it was missing in 38 patients.
When intraprocedure variables were also included, each of the following predictors were significant in descending order of importance: MI 0 to 24 hours before stenting, women with peripheral vascular disease, MI 1 to 30 days before stenting, high-risk intervention, acute closure, preprocedure intravenous heparin, diabetes, and history of cerebrovascular accident or transient ischemic attack (model-adjusted R 2 = 0.39, P = .0001) (Table III) .
After the candidate postprocedure variables were entered into a comprehensive MLR model along with candidate preprocedure and intraprocedure variables, the most predictive, parsimonious model contained the following predictors in descending order of importance: MI 0 to 24 hours, transfusion, postprocedure intravenous heparin, postprocedure intravenous NTG, MI 1 to 30 days, postprocedure IABP, women with peripheral vascular disease, high-risk intervention, preprocedure intravenous heparin, and acute closure. The variable diabetes was also included in the final model, although it was not statistically significant (modeladjusted R 2 = 0.54, P = .0001) (Table IV) .
When candidate adverse outcome variables were entered into a comprehensive MLR model containing candidate preprocedure, intraprocedure, and postprocedure variables, the most predictive, parsimonious model contained the following predictors in descending order of importance: MI 0 to 24 hours, periprocedure ischemia, postprocedure intravenous heparin, periprocedure cerebrovascular accident or transient ischemic attack, women with peripheral vascular disease, preprocedure intravenous heparin, postprocedure IABP, MI 1 to 30 days, postprocedure intravenous NTG, contrast nephropathy, GI bleeding, repeat angiography, vascular complication, high-risk intervention, and arrhythmia. Chronic atrial fibrillation and transfusion were also included in the final model but did not 
LOS after coronary stenting (n = 359).
reach statistical significance (model-adjusted R 2 = 0.61, P = .0001) ( Table V) . Periprocedure angina and periprocedure MI were both significantly predictive of LOS but were highly correlated. To avoid the introduction of multicollinearity into the MLR model, these outcomes were collapsed into a single outcome variable (periprocedure ischemia).
Discussion
In this registry study of patients undergoing coronary stenting with antiplatelet therapy, we identified a number of important clinical, procedural, and treatment factors and adverse clinical outcomes that predict postprocedure LOS. Although preprocedure factors explained more than one third of the variability in Values given are number (percent). postprocedure LOS (adjusted R 2 = 0.37), the inclusion of procedural variables added little to the model (adjusted R 2 = 0.39). Inclusion of nonoutcome postprocedure variables significantly enhanced the predictive capacity of the MLR model, so that more than one half of the variability in postprocedure LOS was explained (adjusted R 2 = 0.54). Interestingly, the addition of outcome variables to the model only increased its predictive capacity to a small degree (adjusted R 2 = 0.61). Nevertheless, the final MLR model including adverse outcomes explained >60% of the variability in postprocedure LOS.
Wolfe et al 17 found that postprocedure adverse clinical outcomes explained more of the variability in LOS after PTCA than did clinical or procedural variables. As in the study of Wolfe et al, when we entered adverse outcomes into a MLR model, they explained more than a third of the variability in log e (LOS) (adjusted R 2 = 0.40, P = .0001; data not shown). However, unlike that study, our clinical and procedural variables were just as predictive as the adverse outcome variables (adjusted R 2 = 0.39, P †Compared with those patients without any history of MI. "Remote MI" did not significantly predict log e (LOS) in any of the selected preliminary models; therefore this variable does not appear in the final model. Table II . MLR model* of log e (LOS) including preprocedure factors, n = 359 = .0001). We also found the addition of therapeutic variables to be useful, be they preprocedure or postprocedure, and when we combined these with clinical, procedural, and adverse outcome variables into a single comprehensive MLR model, it explained the greatest proportion of variability in log e (LOS).
Little has been published about predicting LOS after contemporary coronary stenting. An Italian registry study of 939 patients found that female sex, prior CABG, and nonelective stenting were independent multivariable predictors of LOS. 25 Although we also found that female sex and prior CABG were significant bivariate predictors of LOS, neither were significant independent predictors of postprocedure LOS in our study. Nevertheless, women with peripheral vascular disease had longer hospital stays compared with other patients, suggesting that sex is an important predictor of LOS in certain patient subgroups.
Although these LOS models (in particular those that exclude adverse outcomes) may enable providers, insurers, and payors to develop more accurate risk-adjusted methods, few reversible factors that lengthen hospital stay after coronary stenting were identified. Like our study, others have also found an association between postprocedure intravenous heparin and hospital stay. A recent observational study of patients undergoing coronary stenting or PTCA found that omission of postprocedure intravenous heparin led to decreased LOS without increasing the rate of adverse clinical outcomes. 26 In addition, 2 randomized controlled trials have demonstrated that omission of postprocedure intravenous heparin after successful PTCA for stable or unstable coronary syndromes reduces bleeding complications, shortens LOS, and does not confer greater risk of ischemic complications. 27, 28 Given these findings, most institutions, including our own, no longer routinely administer postintervention intravenous heparin. In addition, our results are consistent with those of an earlier study in which blood transfusions after percutaneous coronary intervention were associated with longer LOS. 29 The majority of these transfusions were unnecessary according to guidelines published at the time. 30 Although we could not assess the appropriateness of blood transfusion in the current study, it is possible that the longer LOS among those who were transfused reflected the use of a more conservative management strategy rather than a true need for transfusion. Efforts are now under way at many institutions to reduce inappropriate blood transfusion practices; it remains to be seen whether reducing transfusion rates will shorten LOS.
Limitations
There are a number of inherent limitations in our study. First, this study was conducted at a single center with a relatively small group of patients. This fact may limit the generalizability of our findings to other centers and different patient populations.
Second, our study was limited in that it was observational. As such, we cannot rule out the possibility that the results were confounded by unmeasured variables or were subject to bias. In particular, adjustments were not made for race or ethnicity, socioeconomic status, social support, or access to medical care because data were not available on these attributes. Each of these factors has been shown to influence the length of hospital stay associated with various medical conditions and procedures. [31] [32] [33] Finally, the rate of adjunctive platelet glycoprotein IIb/IIIa use with coronary stenting has increased significantly since the conclusion of our study. Whether greater use of these agents or advances in stent technology will be associated with reductions in hospital stay remains to be seen. Further studies are needed to validate our findings and assess the role of other factors vis-à-vis LOS after coronary stenting. We are in the process of collecting more recent data from a consortium of 8 academic, tertiary referral, and community hospitals for this purpose. 34 
Conclusion
This study identifies a number of important factors that explain a substantial proportion of the variability in length of hospital stay after coronary stenting. Such information will enable providers, insurers, and payors to develop more accurate risk-adjusted methods with 
